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S U M M A R Y
Objectives: The objective of this study was to assess the epidemiological, laboratory, and clinical features
of imported strongyloidiasis in a tropical medicine referral unit in Madrid, Spain.
Methods: This was a retrospective study based on a review of medical records. A patient was diagnosed
with strongyloidiasis when the infection could be detected by conventional stool analysis and/or
serology against Strongyloides stercoralis, regardless of the presence of symptoms.
Results: One hundred and seventy-eight cases of strongyloidiasis were included in the study. Stool tests
were performed in all patients, and serology in 160 patients (89.9%). The diagnosis of strongyloidiasis
was based on serology only in four patients; 21 patients only had positive stool tests. A third of the total
strongyloidiasis cases in this study were travel-related, mainly associated with short trips (<2 months).
Only 47.8% of total cases were symptomatic. We found no differences in clinical presentation between
immigrants and travelers with strongyloidiasis.
Conclusions: Not only should strongyloidiasis be suspected in symptomatic travelers and immigrants,
but it should also be ruled out when elevated IgE levels or eosinophilia are present. Strongyloidiasis can
be asymptomatic in HIV patients, but it should be diagnosed and treated before a possible
hyperinfection develops.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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Strongyloidiasis is caused by Strongyloides stercoralis, an
intestinal nematode. It is usually acquired by walking barefoot
on infested soil, and is an endemic infection in the tropics and
subtropics. The worldwide prevalence is estimated at between 3
million and 100 million.1 Autochthonous cases have been reported
in Spain, mainly in the Mediterranean area,2–4 but data from cases
in immigrants and travelers are scarce.5–7 Other foci in Europe
have also been reported.8–10
Strongyloidiasis is one of the most difﬁcult parasitic diseases to
diagnose, because there is no gold standard for this purpose. It can* Corresponding author.
E-mail addresses: germanro.76@gmail.com,
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http://dx.doi.org/10.1016/j.ijid.2013.09.009be suspected in symptomatic patients with digestive, respiratory,
or cutaneous complaints; however asymptomatic eosinophilia and
even ‘silent’ infections have also been described. Traditional
diagnostic methods are based on the visualization of S. stercoralis in
stools and the demonstration of antibodies by serology, but the
sensitivity and speciﬁcity can vary in different groups of patients.
Hyperinfection and disseminated infections can be fatal in
immunosuppressed patients (transplant recipients and those on
corticosteroid treatment). Focusing on HIV infection, the preva-
lence of this co-infection is variable;11–13 the most frequently
manifested symptoms are chronic diarrhea, fever, cough, and
unintentional weight loss. S. stercoralis in persons infected with
human T-cell lymphotropic virus type 1 (HTLV-1) is highly
associated with parasite dissemination and the development of
severe strongyloidiasis. These co-infected patients have a modiﬁed
immunological responses against parasite antigens.14,15
Several questions remain to be answered related to imported
strongyloidiasis. How common is strongyloidiasis linked to travel?
What countries are the main sources of infection? Should travelers
and immigrants be tested routinely for strongyloidiasis? The mainociety for Infectious Diseases. Open access under CC BY-NC-ND license.
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laboratory, and clinical features of imported strongyloidiasis in a
tropical medicine referral unit in Madrid. Other goals were to
describe the diagnosis method and to evaluate the differences
between two groups: immunocompetent and immunosuppressed
patients.
2. Methods
Hospital Carlos III is a referral unit for tropical diseases in
Madrid, Spain. Most patients come by themselves to the
emergency unit or are referred from primary care or general
hospitals in Madrid. A very small proportion of patients come from
other regions.
A retrospective study based on a review of the medical records
of adults who attended Hospital Carlos III between January 1, 2007
and December 31, 2011 was performed. Patients with positive
parasite samples for S. stercoralis or positive serology against this
parasite were identiﬁed through the databases of the Microbiology
Department and the Tropical Diseases Unit.
Exclusion criteria were: (1) unspeciﬁed diagnosis methods, and
(2) medical records with a lack of data (>25% items): epidemio-
logical data (>5 items), clinical data (>5 items), and analytical data
(>7 items).
A patient was diagnosed with strongyloidiasis when the
infection could be detected by conventional stool analysis and/
or serology against S. stercoralis, regardless of the presence of
symptoms. Countries considered endemic for Strongyloides were
those on the map published by Stanford University.16
Cases of strongyloidiasis were deﬁned as: (1) autochthonous,
when diagnosed in a person who had never travelled to a country
endemic for Strongyloides; (2) traveler, when a person was
diagnosed after travelling to a country endemic for Strongyloides;
(3) native, when a person was born in a country endemic for
Strongyloides.
For each case, demographic, clinical, and laboratory data were
documented (see Table 1).
Countries were classiﬁed as follows: Africa includes the World
Health Organization (WHO) African Region, Egypt, Libya, Morocco,
Somalia, Sudan, and Tunisia. Asia includes the WHO South-East
Asia Region, Western Paciﬁc Region (excluding Australia),
Afghanistan, and Pakistan. Central and South America includes
the WHO Region of the Americas, excluding the British Virgin
Islands, Canada, and the USA.
Serum samples were tested for the qualitative screening of IgG
antibodies to S. stercoralis using an ELISA technique (DRG
Strongyloides IgG ELISA). The microtest wells were coated with
Strongyloides antigen. One hundred microliters of diluted serum
(1/64) was dispensed into the wells and incubated for 10 min at
room temperature. Next the wells were washed three times with
the washing buffer provided, 100 ml of protein A–peroxidase
conjugate was added, and the mixture was incubated for 5 min at
room temperature. After washing and removing excess moisture,
100 ml of tetramethylbenzidine was then dispensed into each well.Table 1
Data collecteda
Demographic data Age; sex; place of birth; place of residence; last endemic
date of arrival to non-endemic zone for Strongyloides (n
Clinical data Presence of symptoms (yes/no); date of onset of sympto
reﬂux, dyspepsia, abdominal pain, constipation, diarrhea
Laboratory data Hemoglobin (g/dl); white blood cells ( 109/l); total eos
serum level of immunoglobulin E (IU/ml); HIV, HBV, HC
HIV, human immunodeﬁciency virus; HBV, hepatitis B virus; HCV, hepatitis C virus; H
a Clinical deﬁnitions: anemia: hemoglobin <13 g/dl (12 g/dl in females); leukopenia:
eosinophilia: >700  106 eosinophils/l; relative eosinophilia: >7% eosinophils.
b HTLV antibody testing is not routinely performed in clinical practice.After incubation at room temperature, the reaction was stopped by
the addition of 100 ml of 1 M phosphoric acid. A negative control
and a positive control provided by the manufacturer were included
in each assay. The reading of the plates was carried out at 450 nm/
620 nm, subtracting the blank from all wells. In this study we used
a cut-off value of 0.200. A test was considered positive if the index
(ratio of the OD measure of the sample and OD measure of the cut-
off) was >1.1.
Stool samples were tested by microscopic examination of the
stool issued on three consecutive days and by blood–agar culture.
Microscopic diagnosis was based on the observation of larvae in
stool samples (samples were treated in a Mini Parasep SF Faecal
Parasite Concentrator). For the blood–agar culture method, stool
samples were placed on a blood–agar plate and incubated for 7
days. As the larvae crawl over the agar, they carry bacteria with
them, creating visible tracks.
Data were analyzed using SPSS for Windows v. 17.0 (SPSS Inc.,
Chicago, IL, USA). For the univariate analysis of categorical
variables, Pearson’s Chi-square test was used (Fisher’s test when
needed). The Mann–Whitney U-test was used for quantitative
variables. A p-value of <0.05 was considered signiﬁcant.
3. Results
3.1. General features
One hundred and seventy-eight cases of strongyloidiasis were
included in the study. Fifty-eight cases (32.6%) were classiﬁed as
travelers and 120 (67.4%) as natives. There were no autochthonous
cases. The main features of all the strongyloidiasis cases are shown
in Table 2. Equatorial Guinea was the main country where the
infection was acquired in natives (40.8%), followed by Bolivia
(24.2%) and Ecuador (11.7%). The countries visited by the travelers
group were very heterogeneous (Table 2). Reported countries
visited in Africa were Algeria, Angola, Benin, Burkina Faso, Burundi,
Cameroon, Chad, Central African Republic, Congo, DR Congo, Coˆte
D’Ivoire, Equatorial Guinea, Gabon, Kenya, Malawi, Mali, Morocco,
Mauritania, Namibia, Nigeria, Rwanda, Senegal, Tanzania, Togo,
and Zimbabwe. Countries visited in Asia were Afghanistan,
Bangladesh, Cambodia, Malaysia, Nepal, Thailand, and Vietnam.
Countries visited in America were Argentina, Bolivia, Colombia,
Cuba, Costa Rica, Dominican Republic, Ecuador, Guatemala, Haiti,
Honduras, Jamaica, Mexico, Nicaragua, Peru, and Venezuela.
3.2. Symptoms, laboratory abnormalities, and comorbidities
Clinical features of strongyloidiasis are shown in Table 3, and
laboratory abnormalities can be seen in Table 4 and Figure 1. An
asymptomatic infection with eosinophilia >700  106 cells/l was
present in 28% of cases. Eosinophilia was higher (45.2%) in
asymptomatic patients when the cut-off was lower (e.g.
>500  106 cells/l). An asymptomatic infection with normal IgE
levels and with normal eosinophil counts was described in 27 cases
(15.2%). An asymptomatic infection with normal IgE levels and zone for Strongyloides visited; dates of travel (traveler);
ative)
ms; presence of urticaria, larva currens, purpura, nausea, vomiting,
, cough, sputum, wheezing, comorbidity
inophil count ( 106/l); percentage of eosinophils (%); platelet count ( 109/l);
V, and HTLVb antibody testing
TLV, human T-cell lymphotropic virus.
 white blood cells <4  109/l; thrombocytopenia: platelets <150  109/l; absolute
Table 2
Epidemiological features of the patients
Age, years, median (IQR) 37.5 (29–46)
Male, n (%) 76 (42.7%)
Time from arrival to diagnosis, days, median (IQR) 402 (43–2145)e
Autochthonous, n (%) 0 (0)
Travelers,a n (%) 58 (32.6)
Natives, n (%) 120 (67.4)
Travelers: visited region,b n (%)
Africa 19 (32.8)
Asia 5 (8.6)
Central and South America 12 (20.7)
Africa and Asia 5 (8.6)
Africa, Central and South America 9 (15.5)
Asia, Central and South America 4 (6.9)
Africa, Asia, and Central and South America 4 (6.9)
Duration of the travel (travelers), days, median (IQR) 38 (15–182)f
Natives: region of origin, n (%)
Sub-Saharan Africac 60 (50)
Central and South America, including Caribbeand 60 (50)
Time of residence in Spain (natives), years, median (IQR) 3 (0–7)g
HBV infection, n (%) 3 (1.7)
HCV infection, n (%) 6 (3.4)
HIV infection, n (%) 9 (5.1)
HTLV infection, n (%) 0 (0)
Immunosuppression treatment 0 (0)
IQR, interquartile range; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human
immunodeﬁciency virus; HTLV, human T-cell lymphotropic virus.
a Fifty-seven patients from Spain; one patient from France.
b See text for more information about countries visited (one or more countries in
the same trip).
c Natives from Angola, Cameroon, Equatorial Guinea, Mali, Mozambique, Nigeria,
Senegal, and Tanzania.
d Natives from Bolivia, Brazil, Colombia, Ecuador, Honduras, Nicaragua,
Paraguay, Peru, Dominican Republic, and Venezuela.
e From 161 patients.
f From 46 patients.
g From 109 patients.
Table 3
Clinical characteristics of cases of strongyloidiasis (total and by group)
Total (n = 178) (100%), n (%) Travele
Symptomatic, n (%) 85 (47.8) 33 (56.
Gastrointestinal symptoms, n (%) 54 (30.3) 22 (37.
Nausea 4 (2.2) 1 (1.7
Vomiting 4 (2.2) 2 (3.4
Reﬂux 6 (3.4) 1 (1.7
Dyspepsia 13 (7.3) 2 (3.4
Abdominal pain 20 (11.2) 7 (12.
Constipation 8 (4.5) 2 (3.4
Diarrhea 22 (12.4) 18 (31)
Pulmonary symptoms, n (%) 6 (3.4) 1 (1.7
Cough 4 (2.2) 1 (1.7
Sputum 0 (0) 0 (0) 
Wheezing 1 (0.6) 0 (0) 
Cutaneous symptoms, n (%) 38 (21.3) 11 (19)
Urticaria 32 (18) 9 (15.
Larva currens 5 (2.8) 1 (1.7
Purpura 2 (1.1) 0 (0) 
Comorbidity, n (%) 72 (40.4) 13 (22.
NA, not applicable.
a Comparison between travelers and natives.
b Fisher’s exact test.
Table 4
Abnormal laboratory data (total and by group)
Total 
Total eosinophil count ( 106 cells/l), median (IQR) 450 (200–900) 
Percentage of eosinophils, median (IQR) 7.1 (3.4–14.9) 
Serum IgE levels (IU/ml), median (IQR) 326.5 (59–1014.2) 
IQR, interquartile range.
a Comparison between travelers and natives; Mann–Whitney U-test.
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An asymptomatic infection with increased IgE levels and without
eosinophilia (any type) was present in 18 cases (10.1%). There were
no cases of hyperinfection or disseminated infection.
A comorbidity was described in 72 cases (40.4%), mainly other
infectious diseases. There were 22 cases of Chagas disease (12.4%),
nine of ﬁlariasis (5.1%), seven intestinal helminthic infections
(other than strongyloidiasis; 3.9%), and ﬁve cases of malaria (2.8%).
Also described were co-infections with hepatitis B virus (HBV),
hepatitis C virus (HCV), and HIV (Table 2). No cases of HTLV
infection were present. The main non-infectious disease reported
was hypertension (10 cases). The median (range) Charlson index
was 0 (0–7).
3.3. Analysis by groups
There were nine patients considered as immunosuppressed, all
of them HIV-1-infected. The HIV subtypes were the following: B
(three cases), A1, C, CRF02_AF, CRF02_AG, and CRF11; the subtype
of one case was missing. The median (range) total CD4 lymphocyte
count was 313.5 (32–877) cells/mm3; the median (range) viral load
was 1.97 log (1.56–5.23) copies/ml. Only four patients were on
highly active antiretroviral therapy (HAART), three of them with an
undetectable viral load. Another patient was an elite controller. No
cases of co-infection with HBV or HCV were reported.
There were no differences in clinical features in the two groups,
as can be seen in Table 5. In immunosuppressed patients,
cutaneous and respiratory symptoms were only described when
the total CD4 lymphocyte count was <200 cells/mm3, and
digestive symptoms were reported only in patients with >200
cells/mm3. No differences were found in the percentages of
patients with increased IgE levels (63% in immunocompetent vs.
66.7% in immunosuppressed patients; p > 0.999, Fisher’s exactrs (n = 58) (32.6%), n (%) Natives (n = 120) (67.4%), n (%) p-Valuea
9) 52 (43.3) 0.09
9) 32 (26.7) 0.12
) 3 (2.5) >0.99b
) 2 (1.7) 0.59b
) 5 (4.2) 0.66b
) 11 (9.2) 0.23b
1) 13 (10.8) 0.81
) 6 (5) >0.99b
 4 (3.3) <0.001
) 5 (4.2) 0.66b
) 3 (2.5) >0.99b
0 (0) NA
1 (0.8) >0.99b
 27 (22.5) 0.59
5) 23 (19.2) 0.55
) 4 (3.3) >0.99b
2 (1.7) >0.99b
8) 59 (49.2) 0.001
Travelers Natives p-Valuea
200 (150–400) 600 (300–1050) <0.001
3.4 (2.45–5.45) 10.7 (5.6–16.9) <0.001
58 (23.15–147.5) 642 (191–1279) <0.001
Figure 1. Laboratory abnormalities: serum IgE levels from 162 cases.
Table 5
Clinical features of strongyloidiasis in immunocompetent and immunosuppressed patientsa
Immunocompetent
(n = 165)
Immunosuppressed
(n = 9)
p-Valueb
Symptomatic, n (%) 78 (47.3) 4 (44.4) >0.999
Gastrointestinal symptoms, n (%) 50 (30.3) 2 (22.2) 0.726
Pulmonary symptoms, n (%) 5 (3) 1 (11.1) 0.276
Cutaneous symptoms, n (%) 35 (21.2) 2 (22.2) >0.999
a Data from 174 patients.
b Fisher’s exact test.
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immunocompetent patients than in immunosuppressed patients
(27.3% vs. 77.8%; p = 0.003, Fisher’s exact test). Relative eosino-
philia was also less frequent in immunocompetent patients (46.7%
vs. 88.9; p = 0.016, Fisher’s exact test).
3.4. Diagnosis methods
Stool tests were performed in all patients, and serology in
160 patients (89.9%). The diagnosis of strongyloidiasis was based
on serology only in four patients (two travelers and two
natives); 21 patients (six travelers and 15 natives) had only stool
tests positive. Three cases of strongyloidiasis (all in travelers)
were positive by stool tests but negative by serology. In HIV
patients with strongyloidiasis, stool tests were positive for all
patients; serology was also positive for all patients tested
(77.8%).
Abnormal laboratory ﬁndings depending on the method of
diagnosis are shown in Figure 2.Figure 2. Percentage of abnormal laboratory tests4. Discussion
To our knowledge, this is the largest reported series of imported
strongyloidiasis in Europe. Most reported cases of imported
strongyloidiasis have been related to immigrants from endemic
zones. In this study, travel-related strongyloidiasis constituted a
third of the total (similar to the ﬁndings of Nuesch et al.17), and the
origin of acquisition in this group was very heterogeneous. More
than half of the strongyloidiasis cases in travelers were acquired in
trips of less than 2-month duration, suggesting that some of the
recommendations regarding screening tests in travelers may be
debated.18,19 Only two thirds of cases of strongyloidiasis in our
study were in natives, with a ratio of origin Africa to Central and
South America of 1; no cases were from Asia. In this group of
patients, some of the diagnoses had been delayed for a long time.
Similar to Gonza´lez et al.,5 we found no differences in clinical
presentation between natives and travelers. However, eosinophilia
(absolute and relative) and levels of serum IgE were higher in
natives. Comorbidities were present in nearly half of the cases, but regarding positive tests for strongyloidiasis.
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index). We found no cases of hyperinfection or disseminated
infection. This could be explained by the following: (1) cortico-
steroid therapy is the most frequent associated condition, and we
had no patients on this therapy;20 (2) other risk factors such as
malignancy, organ transplantation, HTLV-1 infection, and diabetes
were not found in our series; (3) very few cases of hyperinfection
and disseminated strongyloidiasis in HIV-infected individuals have
been reported in the medical literature; and (4) although the
median time to diagnosis was delayed up to 1 year, perhaps it was
made early enough to prevent the development of a hyperinfec-
tion/disseminated infection.
A secondary purpose of this retrospective study was to
describe the major clinical features of immunosuppressed
patients. We were only able to ﬁnd HIV-infected patients in this
series. When AIDS was initially described, an outbreak of
disseminated strongyloidiasis was predicted; however the rela-
tive paucity of cases led the US Centers for Disease Control and
Prevention (CDC) and the WHO to remove disseminated
strongyloidiasis from the list of signature infections. However,
strongyloidiasis is more prevalent in HIV patients in endemic
zones.11,12 It has been reported that the rate of parasitic infection
increases with decreasing CD4 T-cell counts among HIV-infected
individuals.12 In our study, a signiﬁcant ﬁnding in HIV patients
was the difference in clinical presentation depending on the total
CD4 lymphocyte count. Of note, even in HIV patients on HAART
with good CD4 counts, stool tests were positive. General
conclusions cannot be drawn from this ﬁnding, because a
limitation of this study was the small number of HIV patients
included; but this should be investigated further. Unlike other
studies,21 we found that eosinophilia was less frequent in
immunocompetent patients than in HIV patients.
The sensitivity of the classic stool microscopy examination
(parasitic ova and larvae) varies between 75.9% and 92%,
depending on the number of samples analyzed.22 Of note, a
negative result does not necessarily indicate the absence of the
infection.23 ELISA serologic assays measure IgG responses to a
crude extract of the ﬁlariform larvae of Strongyloides sp. ELISA
tests for antibodies in serum have a high sensitivity (83–93%) and
speciﬁcity (95–98%).24 It takes 4–6 weeks for these tests to
become positive, and they may remain positive after treatment
for extended periods of time. In acute infections this can lead to
false-negative results, and cross-reactivity with other helminthic
infections has been described.25 There is difﬁculty in calculating
diagnostic efﬁciency parameters for ELISA techniques because of
the absence of a deﬁnitive gold standard for diagnosing S.
stercoralis infection. Speciﬁcally, the test used in our study has
been used by other authors for the diagnosis of both cutaneous
and intestinal strongyloidiasis, with a sensitivity of 89% and a
speciﬁcity of 97.2%, although ﬁlariasis patients were not included
in the calculation of sensitivity and speciﬁcity with this test.26
Bon et al.27 described an increased sensitivity of 91.2%, with a
speciﬁcity of 93.3%, using a large panel of serum samples
collected from patients, including some with a deﬁnitive
diagnosis of strongyloidiasis, some with other helminthic
infections, and some with eosinophilia without a parasitic
infection diagnosis. Experts of the British Infection Society have
suggested performing concentrated stool microscopy and Stron-
gyloides serology in all cases of subjects with a consistent travel
history, symptoms, and/or eosinophilia.7 In our daily clinical
practice, stool tests are performed for all travelers and immi-
grants; serology for Strongyloides is usually solicited when
abnormal laboratory results or symptoms are present. We can
suggest from our results that elevated serum IgE levels are the
most sensitive clue for suspecting strongyloidiasis, followed
by relative eosinophilia. The percentage of patients witheosinophilia or elevated serum IgE levels is greater when
Strongyloides can be detected in stools. This probably reﬂects a
longer period of immunological stimulation until the biological
cycle is completed and the parasite is excreted in the stools. The
fact that more than 50% of the strongyloidiasis in this series was
detected in asymptomatic patients, points to the respective risk of
missing the diagnosis.
Azole drugs (thiabendazole, mebendazole, albendazole) and
ivermectin have been used for the treatment of strongyloidiasis.
Currently, ivermectin is the best therapeutic option for
strongyloidiasis. The most recent trials comparing ivermectin
and azole drugs have shown the superiority and better tolerance
of the former28–30. Most patients in the study were treated with
ivermectin, customized to the different status of immunity.
In conclusion, not only must strongyloidiasis be suspected in
symptomatic travelers and immigrants, but it should also be ruled
out when elevated IgE levels or eosinophilia are present.
Strongyloidiasis can be asymptomatic in HIV patients, but it
should be diagnosed and treated before a possible hyperinfection
develops.
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